NutriStack
What is happening. Telmisartan, an angiotensin II receptor blocker, reduces aldosterone secretion and thereby decreases urinary potassium excretion. Co-administration with potassium supplements (or potassium-containing salt substitutes) can produce additive increases in serum potassium, with a real risk of clinically significant hyperkalemia, particularly in patients with chronic kidney disease, diabetes, heart failure, or the elderly.
Mechanism. ARB-mediated suppression of the renin-angiotensin-aldosterone system lowers aldosterone, reducing renal potassium excretion; supplemental potassium adds an exogenous load that the kidney cannot clear, raising serum potassium.
Recommendation. Avoid routine potassium supplementation and potassium-based salt substitutes unless specifically directed and monitored by a clinician. If potassium must be used, check baseline serum potassium and renal function, then recheck within 1 to 2 weeks of starting or changing either agent. Report muscle weakness, palpitations, or irregular heartbeat promptly.